Newer drug therapies have expanded the scope of treatment for patients with JSpA. bDMARDs such as adalimumab, etanercept, infliximab, and secukinumab have demonstrated clinically significant treatment efficacy in ERA and JPsA. Based on extrapolation studies, intravenous golimumab, etanercept, abatacept, and ustekinumab have gained Food and Drug Administration (FDA) approval for JPsA. Long-term follow-up studies continue to demonstrate acceptable safety profiles. There is need for more real-world data on drug efficacy from Registry studies and research on effective de-escalation strategies.
Keyphrases
- ankylosing spondylitis
- rheumatoid arthritis
- drug administration
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- case control
- ulcerative colitis
- high dose
- stem cells
- emergency department
- adverse drug
- low dose
- combination therapy
- deep learning
- risk assessment
- artificial intelligence
- drug induced
- human health
- cell therapy